Diabetes
Innovent Scores Phase 3 Success with Lilly’s Pioneering Obesity Drug for Diabetes Management
Innovent Biologics, Eli Lilly, obesity drug, diabetes management, phase 3 trials, collaboration, metabolic disorders, weight loss, glucose control, next-generation therapy.
Novo Nordisk Faces Scrutiny Over High Prices of Ozempic and Wegovy
Novo Nordisk, Ozempic, Wegovy, drug prices, Senator Bernie Sanders, diabetes, obesity
Senator Sanders Investigates Skyrocketing Costs of Novo Nordisk’s Diabetes and Weight Loss Drugs
Senator Bernie Sanders, Novo Nordisk, diabetes, weight loss, drug prices, Novos Ozempic, Wegovy, investigation, healthcare costs, affordability
EMA Dispels Link Between GLP-1 Receptor Agonists and Suicidal Ideation Risk New
EMA, GLP-1 receptor agonists, Diabetes and weight-loss drugs, Suicidal ideation risk, No causal association, Pharmacovigilance activities, Continued monitoring